Resources

Merck's record-breaking $10 billion acquisition of Verona Pharma illustrates the potential of our sector but also is a reminder of the need to strengthen UK capital markets.

In this blog, James Buckley-Walker, Partner, 3PM, shares his vision of a smarter, more human-focused approach to lab design and operation.

Today, the British Business Bank has announced a new £400 million Investor Pathways Capital initiative, which will support diverse and emerging fund managers across the economy and make it easier for new entrants, particularly those from underrepresented groups, to break into venture capital.

In this article, Kate Barclay, Skills Strategy Consultant at BIA, outlines new changes to UK immigration law and how they will impact the life sciences sector. Prepared in collaboration with legal experts at Eversheds-Sutherland LLP.

In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, shares the vision of hope witnessed at BIA's recent TechBio X event in Cambridge.

Coulter Partners successfully completed a search assignment for Biomia and is pleased to announce the placement of Frederick Westhorpe, PhD as Chief Scientific Officer (CSO).

NHS 10 Year Health Plan for England, a strategy for European Life Sciences and hope to see you at the “sunny” BIA Summer Party on Wednesday.

In this blog, Sarah Potter, Partner - Patent Attorney and Robert Cogger-Ward, Associate at Potter Clarkson, share what you need to know about DSI and the Cali Fund.

Coulter Partners successfully completed search assignments for Augustine Therapeutics NV.

Hosted at West Road Concert Hall in Cambridge, the Symposium brings together leading minds from academia and industry to showcase cutting-edge research and its translation into novel therapeutics.

Their vanguard, breakthrough proteomics platform technology unlocks full-length protein sequencing and characterisation, accelerating drug development and diagnostics.

Rinri Therapeutics is focused on transforming sensorineural hearing loss (SNHL) with regenerative cell therapy, providing new therapeutic options for the treatment of this major global unmet medical need.

Cancer Research Horizons, the innovation arm of Cancer Research UK, has appointed its first Clinical Advisory Board to provide strategic guidance on the development of novel cancer therapeutics emerging from its drug discovery division, Therapeutic Innovation.

OK, I admit defeat. The UK government has published 3.5 key strategies that affect our sector in a week and I’m expecting at least two more in the coming days – a full analysis of so much text by today is beyond me but…

Laverock Therapeutics closes additional seed funding round, bringing total raised to more than £20 million.

In this latest white paper, Dave Cooper, Project Pursuit Manager at Emerson, explores how forward-thinking biotech companies can meet the growing demand for personalised treatments by reimagining their manufacturing strategies.

OutSee, announced it has secured £1.8 million in seed funding, led by Ahren Innovation Capital and with additional investment from Kadmos Capital, Empirical Ventures and Panacea Ventures.

Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of semaglutide treatment; Initial proof-of-concept data expected in second half of 2026